BIOCRYST INITIATES PHASE IB TRIAL OF BCX-4208
BioCryst Pharmaceuticals announced that it has initiated a Phase Ib trial of BCX-4208, the company's second generation, transition-state analog inhibitor of purine nucleoside phosphorylase.
Being conducted in healthy volunteers, the trial is designed to evaluate the safety, tolerability, and pharmacokinetics of multiple oral doses of BCX-4208.
The single-center study is being conducted as a randomized, double-blind, placebo-controlled, dose-escalating trial consisting of three dose groups. Groups of ten subjects (eight on active drug, two on placebo) will receive 0.5 mg/kg, 1.5 mg/kg or 2.5 mg/kg oral doses of BCX-4208 once daily for seven days. All doses will be administered two hours prior to breakfast after an overnight fast. The study is scheduled to enroll 30 healthy adult subjects.
Upcoming Events
-
21Oct